Corvus Pharmaceuticals, Inc.
CRVS
$3.24
$0.010.31%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -62.29M | -56.83M | -22.62M | -24.86M | -27.03M |
| Total Depreciation and Amortization | 85.00K | 93.00K | 102.00K | 117.00K | 151.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 38.43M | 35.19M | 2.62M | 4.88M | 6.54M |
| Change in Net Operating Assets | -1.65M | -579.00K | -1.35M | -1.12M | -3.59M |
| Cash from Operations | -25.42M | -22.13M | -21.24M | -20.98M | -23.94M |
| Capital Expenditure | -- | 0.00 | 0.00 | 0.00 | -34.00K |
| Sale of Property, Plant, and Equipment | 5.00K | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -27.49M | -23.72M | -2.28M | 10.93M | 15.58M |
| Cash from Investing | -27.48M | -23.72M | -2.28M | 10.93M | 15.54M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 35.06M | 16.46M | 16.74M | 7.85M | 7.86M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 13.97M | 13.97M | 13.97M | -- | -- |
| Cash from Financing | 49.03M | 30.42M | 30.71M | 7.85M | 7.86M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3.88M | -15.43M | 7.18M | -2.20M | -539.00K |